Affiliation: University of Sydney
- Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID StudyWendy E Hague
From National Health and Medical Research Council Clinical Trials Centre, University of Sydney, New South Wales, Australia W E H, J S, A K, A C K, H P Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand H D W, R A S Department of Cardiology, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia D H Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia P J N Greenslopes Hospital, Brisbane, Queensland, Australia D M C Royal Prince Alfred Hospital, Sydney, New South Wales, Australia D R S University of Western Australia, Perth, Australia P L T University of Queensland, Brisbane, Queensland, Australia M W Faculty of Health Sciences and Medicine, Bond University, Queensland, Australia P P G and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia A M T
Circulation 133:1851-60. 2016....
- Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyWendy Hague
NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
Am Heart J 145:643-51. 2003..The aim of this subgroup analysis was to assess the effects of pravastatin in women...
- Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialAnthony Keech
National Health Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
Diabetes Care 26:2713-21. 2003..0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG)...
- Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia
Circulation 105:1162-9. 2002..0 to 7.0 mmol/L at baseline. Secondary objectives included assessment of CHD event reduction according to lipid levels...
- Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker studyAndrew M Tonkin
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Electronic address
Int J Cardiol 201:499-507. 2015..whether changes in concentrations of these biomarkers over 12 months affected subsequent CHD risk; and 3. whether pravastatin modified the change in biomarker concentrations and this influenced the risk of future events...
- Low-dose aspirin for preventing recurrent venous thromboembolismTimothy A Brighton
Department of Haematology, South Eastern Area Laboratory Services SEALS, Prince of Wales Hospital, Sydney, Australia
N Engl J Med 367:1979-87. 2012..Patients who have had a first episode of unprovoked venous thromboembolism have a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effective in preventing a recurrence of venous thromboembolism...
- Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical TrialAndrew R L Stevenson
Faculty of Medicine and Biomedical Sciences, University of Queensland, Brisbane, Australia2Royal Brisbane and Women s Hospital, Brisbane, Australia
JAMA 314:1356-63. 2015..Because of anatomical constraints, laparoscopic rectal resection may not be better because of limitations in performing an adequate cancer resection...